NCT06903884View on ClinicalTrials.gov

3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions
Vernal Keratoconjunctivitis
Interventions
DRUG

3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion

This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

DRUG

0.1% Cyclosporin A cationic ophthalmic emulsion

This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

All Listed Sponsors
lead

The University of Hong Kong

OTHER